Document is current
Any future updates will be listed below
-
Authors
Lam, Dilys
Luu, Phuc-Loi
Song, Jenny Z.
Qu, Wenjia
Risbridger, Gail P.
Lawrence, Mitchell G.
Lu, Jennifer
Trau, Matt
Korbie, Darren
Clark, Susan J.
Pidsley, Ruth
Stirzaker, Clare https://orcid.org/0000-0001-5601-3140
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (1106870)
National Health and Medical Research Council (1063669)
National Health and Medical Research Council (1156408)
National Health and Medical Research Council (1002648)
National Health and Medical Research Council (1102752)
Cancer Australia (1044458)
National Breast Cancer Foundation (IIRS-18-137)
National Foundation for Medical Research and Innovation
Cancer Council NSW (RG-18-09)
Victorian Cancer Agency (MCRF18017)
- License Information
-
More Information
Article History
Received: 18 February 2020
Accepted: 4 June 2020
First Online: 22 June 2020
Ethics approval and consent to participate
: cfDNA samples for this study were obtained with ethical approval from the Bellberry Human Research Ethics Committee (Application 2015-12-817-PRE-4). Patient samples for primary fibroblasts were obtained with written informed consent with human ethics approval from Monash University (2004/145) and Cabrini Hospital (03-14-04-08). Human tissue samples representing normal and tumour breast from formalin-fixed paraffin-embedded tissue were as described in Stirzaker et al. 2015 []. The study protocol was approved by the Hunter New England Research Ethics Committee (NSW HREC reference no.: HREC/09/HNE/153), Newcastle, New South Wales and Princess Alexandra Hospital Human Research Ethics Committee (PAH HREC) (research protocol: 2007/165) Brisbane, Queensland.
: Not applicable
: The authors declare that they have no competing interests.
